Kalaris Financial Statements From 2010 to 2026

KLRS Stock   8.98  0.66  6.85%   
Kalaris Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Kalaris Therapeutics' valuation are provided below:
Market Capitalization
180.3 M
Earnings Share
(38.05)
There are over one hundred available fundamental ratios for Kalaris Therapeutics, which can be analyzed over time and compared to other ratios. All traders should check Kalaris Therapeutics' last-minute fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 23.4 M in 2026. Enterprise Value is likely to gain to about (62.1 M) in 2026
Check Kalaris Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kalaris Therapeutics' main balance sheet or income statement drivers, such as Total Revenue of 0.0, Other Operating Expenses of 55.9 M or Research Development of 10.6 M, as well as many indicators such as Price To Sales Ratio of 71.68, Dividend Yield of 0.0 or PTB Ratio of 0.49. Kalaris financial statements analysis is a perfect complement when working with Kalaris Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Kalaris Stock
Check out the analysis of Kalaris Therapeutics Correlation against competitors.
For more information on how to buy Kalaris Stock please use our How to Invest in Kalaris Therapeutics guide.

Kalaris Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets108.3 M106.7 M80.3 M
Slightly volatile
Other Current Liabilities5.4 M4.5 M3.8 M
Slightly volatile
Total Current Liabilities8.9 M4.7 M7.1 M
Slightly volatile
Current Deferred Revenue2.1 M2.4 M2.6 M
Slightly volatile
Accounts Payable269.8 K284.1 KM
Slightly volatile
Cash84.1 M136 M56.2 M
Slightly volatile
Non Currrent Assets Other1.3 M1.3 M544.9 K
Slightly volatile
Cash And Short Term Investments100.6 M106.5 M75.7 M
Slightly volatile
Net Receivables42.8 K45 K236.2 K
Slightly volatile
Common Stock Shares Outstanding3.5 M5.8 M3.2 M
Slightly volatile
Liabilities And Stockholders Equity108.3 M106.7 M80.3 M
Slightly volatile
Other Current Assets219.7 K231.3 K739.3 K
Pretty Stable
Other Stockholder EquityB952.7 M223.4 M
Slightly volatile
Total Liabilities5.7 MM13.5 M
Slightly volatile
Total Current Assets102.1 M106.7 M76.7 M
Slightly volatile
Short and Long Term Debt Total2.8 M2.9 M10.1 M
Slightly volatile
Property Plant And Equipment Net19.4 M36 M18.3 M
Slightly volatile
Short Term Investments39.7 M41.8 M67.7 M
Pretty Stable
Non Current Liabilities Total53.6 M51.1 M19.9 M
Slightly volatile
Short Term Debt4.7 M7.6 M4.3 M
Slightly volatile
Common Stock5.6 K6.3 K6.9 K
Slightly volatile
Long Term Debt2.6 M2.9 M3.2 M
Slightly volatile

Kalaris Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses55.9 M63.5 M30.2 M
Slightly volatile
Research Development10.6 M11.1 M15.2 M
Slightly volatile
Total Operating Expenses55.7 M63.5 M30.1 M
Slightly volatile
Depreciation And Amortization1.3 M1.3 M433.2 K
Slightly volatile
Cost Of Revenue654.5 K1.3 M424.1 K
Slightly volatile
Income Tax Expense805.6 K906.3 K989.2 K
Slightly volatile
Interest Expense507.1 K790 K336.8 K
Slightly volatile
Selling General Administrative1.6 M1.6 M2.1 M
Slightly volatile

Kalaris Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Change In Cash26.6 M25.4 M28.5 M
Very volatile
Other Non Cash Items12.3 M18.8 M6.9 M
Slightly volatile
Total Cash From Financing Activities18 K18.9 K38 M
Very volatile
End Period Cash Flow84.1 M136 M56.2 M
Slightly volatile
Begin Period Cash Flow55.4 M103.6 M40.3 M
Slightly volatile
Depreciation1.3 M1.3 M433.2 K
Slightly volatile
Net Borrowings5.7 M6.9 M4.7 M
Slightly volatile
Stock Based Compensation167.6 K133.2 K242.3 K
Slightly volatile
Other Cashflows From Financing Activities6.7 M7.4 M8.3 M
Slightly volatile
Issuance Of Capital Stock6.1 M6.1 MM
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio71.6814179.7638
Slightly volatile
Days Sales Outstanding1.2 K1.1 K623
Slightly volatile
Capex To Depreciation0.02540.026810.6933
Slightly volatile
Payables Turnover0.080.120.0922
Slightly volatile
Research And Ddevelopement To Revenue92.9588.5246.1821
Slightly volatile
Capex To Revenue1.641.852.0181
Slightly volatile
Cash Per Share25.827.1635.1579
Pretty Stable
Days Payables Outstanding2.2 K2.5 K2.7 K
Slightly volatile
Current Ratio27.3226.0211.0897
Slightly volatile
Receivables Turnover0.320.342.1325
Slightly volatile
Capex Per Share0.01040.0110.0858
Slightly volatile
Revenue Per Share0.06370.0670.2405
Slightly volatile
Interest Debt Per Share0.170.15183.6281
Slightly volatile
Debt To Assets0.790.750.295
Slightly volatile
Operating Cycle1.2 K1.1 K623
Slightly volatile
Days Of Payables Outstanding2.2 K2.5 K2.7 K
Slightly volatile
Ebt Per Ebit0.780.960.8212
Slightly volatile
Quick Ratio27.3226.0211.0897
Slightly volatile
Net Income Per E B T0.810.910.9887
Slightly volatile
Cash Ratio21.3420.328.6885
Slightly volatile
Days Of Sales Outstanding1.2 K1.1 K623
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.151.0255
Slightly volatile
Fixed Asset Turnover0.01090.01230.0134
Slightly volatile
Debt Ratio0.790.750.295
Slightly volatile
Price Sales Ratio71.6814179.7638
Slightly volatile
Asset Turnover0.00130.00140.0243
Slightly volatile

Kalaris Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap23.4 M41.1 M28 M
Slightly volatile

Kalaris Fundamental Market Drivers

About Kalaris Therapeutics Financial Statements

Kalaris Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Kalaris Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Kalaris Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Kalaris Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue2.4 M2.1 M
Cost Of Revenue1.3 M654.5 K
Research And Ddevelopement To Revenue 88.52  92.95 
Capex To Revenue 1.85  1.64 
Revenue Per Share 0.07  0.06 
Ebit Per Revenue(186.10)(176.79)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Kalaris Stock Analysis

When running Kalaris Therapeutics' price analysis, check to measure Kalaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalaris Therapeutics is operating at the current time. Most of Kalaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kalaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalaris Therapeutics' price. Additionally, you may evaluate how the addition of Kalaris Therapeutics to your portfolios can decrease your overall portfolio volatility.